Good points those, thankfully with the human healthcare side performing, it appears all growth/additional studies in the Medivet business can be funded through existing cash-flows.
MrsB, I know 17m Revenue seems a bit of a stretch, however a couple larger deals in each of the remaining quarters, especially as a result of the new expanded sales team, building on experience and client networks and I don't think it's too far fetched, but time will tell. Have to wait until end of April for the next Quarterly.
in other media:
Another positive stem cell news story posted a couple days back: